Histological outcome of chronic hepatitis B in children treated with interferon alpha

World Journal of Gastroenterology

Volumn 11, Issue 45, 2005, Pages 7179-7182

  Sobaniec Lotowska, Maria Elzbieta ^a   Lebensztejn, Dariusz Marek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Children; Chronic hepatitis B; Fibrosis stage; Inflammation grade; Interferon alpha; Semiquantitative scoring systems

Indexed keywords

ALPHA INTERFERON;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFICACY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 31544448281     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i45.7179     Document Type: Article

References (32)

1. Bortolotti F. Treatment of chronic hepatitis B in children. J Hepatol 2003; 39 (Suppl 1): S200-S205
2. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
3. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-1417
4. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520
5. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20
6. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435
7. Woynarowski M, Socha J, Słuzewski J, Chmurska-Motyka T, Mizerski J, Czerwionka-Szaflarska M, Mikina M, Karczewska K, Lebensztejn D, Zaleska I, Chlebcewicz-Szuba W, Smukalska E, Korzon M, Wysocki J, Strawinska E, Kowalik-Mikolajewska B, Kuydowicz J, Kownacka M, Kowalczyk J, Mierzejewska-Rudnicka A, Trocha H, Planeta-Malecka I, Wozniakowska-Gesicka T, Wozniak M. HBeAg clearance rate and interferon alfa dose. Pediatric Gastroenterology 2004: 253 - 256.
8. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 2003; 38: 223-229
9. Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, Qiu DK, Cao AP, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol 2003; 9: 2574-2578
10. Assy N, Minuk G. A comparison between previous and present histologic assessments of chronic hepatitis C viral infections in humans. World J Gastroenterol 1999; 5: 107-110
11. Acute and chronic hepatitis revisited. Review by an international group. Lancet 1977; 2: 914-919
12. Vajro P, Migliaro F, Fontanella A, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998; 61: 219-223
13. Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23: 131 - 137
14. Ruiz-Moreno M, Rua MJ, Molina J, Moraleda G, Moreno A, Garcia-Aguado J, Carreno V. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991; 13: 1035-1039
15. Gregorio GV, Jara P, Hierro L, Diaz C, de la Vega A, Vegnente A, Iorio R, Bortolotti F, Crivellaro C, Zancan L, Daniels H, Portmann B, Mieli-Vergani G. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700-707
16. Cullu F, Tumay GT, Kutlu T, Erkan T, Ozbay G, Badur S. Treatment of chronic viral hepatits B in children with moderate doses of alpha interferon. Gastroenterol Clin Biol 1995; 19: 53-57
17. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995
18. Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E, Camarena C, De La Vega A, Diaz C, De Moliner L, Noventa F. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998; 29: 184-190
19. Ruiz-Moreno M, Otero M, Millan A, Castillo I, Cabrerizo M, Jimenez FJ, Oliva H, Ramon y Cajal S, Carreno V. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999; 29: 572-575
20. Ozer E, Ozer E, Helvaci M, Yaprak I. Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy. Liver 1999; 19: 369-374
21. Fujisawa T, Komatsu H, Inui A, Sogo T, Miyagawa Y, Fujitsuka S, Sekine I, Kosugi T, Inui M. Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr 2000; 30: 201-206
22. Capra F, Casaril M, Gabrielli GB, Tognella P, Rizzi A, Dolci L, Colombari R, Mezzelani P, Corrocher R, De Sandre G. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers. J Hepatol 1993; 18: 112-118
23. Nakano Y, Kiyosawa K, Sodeyama T, Tanaka E. Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis. Am J Gastroenterol 1990; 85: 24-29
24. Okuno T, Shindo M, Arai K, Matsumoto M, Takeda M. Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes. Gastroenterol Jpn 1990; 25: 70-77
25. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, Mills AS, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-1172
26. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378-386
27. Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, Suzuki Y, Kobayashi M, Murashima N, Ikeda K. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. J Hepatol 1997; 27: 49-55
28. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998; 43: 2573-2576
29. Han HL, Lang ZW. Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment. World J Gastroenterol 2003; 9: 117-121
30. Williams SJ, Craig PI, Cooksley WGE, Bye WA, Bilous M, Grierson JM, Nightingale BN, Burnett L, Hensley WJ, Batey RG. Randomised controlled trial of recombinant human interferon alpha A for chronic active hepatitis B. Aust N Z J Med 1990; 20: 9-19
31. Caballero T, Perez-Milena A, Masseroli M, O'Valle F, Salmeron FJ, Del Moral RM, Sanchez-Salgado G. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responders and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001; 34: 740- 747
32. Lenzen S. Proceedings: Studies on the inhibitory effect of thyroxine on insulin secretion from the perfused rat pancreas. Naunyn Schmiedebergs Arch Pharmacol 1975; 287 Suppl: R58